AbbVie To Acquire Capstan Therapeutics In Up To $2.1 Bln All-Cash Deal
30/6 14:51
(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) and privately-held clinical-stage biotechnology company Capstan Therapeutics, Inc., announced Monday a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tL...